Abstract

The dementia epidemic is likely to expand worldwide as the aging population continues to grow. A better understanding of the molecular mechanisms that lead to dementia is expected to reveal potentially modifiable risk factors that could contribute to the development of prevention strategies. Alzheimer’s disease is the most prevalent form of dementia. Currently we only partially understand some of the pathophysiological mechanisms that lead to development of the disease in aging individuals. In this study, Switch Miner software was used to identify key switch genes in the brain whose expression may lead to the development of Alzheimer’s disease. The results indicate that switch genes are enriched in pathways involved in the proteasome, oxidative phosphorylation, Parkinson’s disease, Huntington’s disease, Alzheimer’s disease and metabolism in the hippocampus and posterior cingulate cortex. Network analysis identified the krupel like factor 9 (KLF9), potassium channel tetramerization domain 2 (KCTD2), Sp1 transcription factor (SP1) and chromodomain helicase DNA binding protein 1 (CHD1) as key transcriptional regulators of switch genes in the brain of AD patients. These transcriptions factors have been implicated in conditions associated with Alzheimer’s disease, including diabetes, glucocorticoid signaling, stroke, and sleep disorders. The specific pathways affected reveal potential modifiable risk factors by lifestyle changes.

Highlights

  • Dementia affects over 50 million people worldwide, approximately 67% of which have Alzheimer’s disease (AD) [1]

  • The results show that the switch genes in the HIP and posterior cingulate cortex (PCC) regions of the brain that are affected in AD patients are enriched in proteasome, oxidative phosphorylation, metabolic, Parkinson’s disease, Huntington’s disease, and Alzheimer’s disease pathways

  • Our results showed that switch genes in the entorhinal cortex (EC), middle temporal gyrus (MTG), visual cortex (VCX) and superior frontal gyrus (SFG) are not enriched in any particular pathways

Read more

Summary

Introduction

Dementia affects over 50 million people worldwide, approximately 67% of which have Alzheimer’s disease (AD) [1]. By 2050 it is predicted that as many as 152 million people may have dementia [1]. There remains no cure for AD and only four drugs have been approved for treatment that manages symptoms of dementia in some patients. We currently do not completely understand the cause of AD, but there is strong data to support the involvement of the proteins amyloid and tau. In AD patients, amyloid-ß and hyperphosphorylated tau are produced abundantly in the brain.

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.